EFFECT OF DAPAGLIFLOZIN ON CARDIAC FUNCTIONAL STATUS IN CHRONIC HEART FAILURE WITH ANEMIA
Abstract
We compared the effect of a standard treatment regimen containing the glucose sodium cotransporter type 2 inhibitor dapagliflozin (Forsiga) on intracardiac hemodynamics in anemic patients with chronic heart failure. In the group of patients who received dapagliflozin, the indicators of intracardiac hemodynamics, in particular, left ventricular diastolic and systolic volume, diastolic volume, and ejection fraction increased significantly after treatment, proving the cardioprotective effect of the drug.
Keywords
chronic heart failure, dapagliflozin, intracardiacHow to Cite
References
Ansary TM, Nakano D, Nishiyama A. Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System. Int J Mol Sci.2019;20(3):629. doi:10.3390/ijms20030629.
Aбдуллaeв Т.A., Цoй И.A. Прoблeмa aнeмичeскoгo синдрoмa при ХСН: критичeский oбзoр рeзультaтoв исслeдoвaния RED-HF и сoбствeнныe дaнныe/ Журнaл сeрдeчнaя нeдoстaтoчнoсть. Мoсквa 2016, №3 С.44-65.
Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17(12):761-72. doi:10.1038/s41569-020-0406-8.
Docherty KF, Petrie MC. Sodium-glucose cotransporter 2 inhibitors as a treatment for heart failure. Heart. 2022;108(4):312-320. doi: 10.1136/heartjnl-2020-318658.
Gadayev A.G., Turaqulov R.I., Kurbanov A.K., Rahimova M.E. Role of Hepcidin and Pro-Inflammatory Cytocines in Chonic Heart Failure in Combination with Anemia // Central Asian Journal of medicine.-2019., Vol.2019: Iss 3, Article 11., P. 81-92.
Karg, M.V.; Bosch, A.; Kannenkeril, D.; Striepe, K.; Ott, C.; Schneider, M.P.; Boemke-Zelch, F.; Linz, P.; Nagel, A.M.; Titze, J.; et al. SGLT-2-Inhibition with Dapagliflozin Reduces Tissue Sodium Content: A Randomised Controlled Trial. Cardiovasc. Diabetol. 2018, 17, 5.
Lambers Heerspink, H.J.; de Zeeuw, D.; Wie, L.; Leslie, B.; List, J. Dapagliflozin a Glucose-Regulating Drug with Diuretic Properties in Subjects with Type 2 Diabetes. Diabetes Obes. Metab. 2013, 15, 853–862.
Marazia S., Loderini S., Magliari F., Sarullo F.M., Di Mauro M. Sucrosomial iron supplementation can be a useful support treatment in patients with heart failure and anemia. In: Materials of 5th International Multidisciplinary Course on Iron Anemia. Florence, Italy. March 31 — April 1, 2017.
Rizzo C, Carbonara R, Ruggieri R, et al. Iron deficiency: a new target for patients with heart failure. Front Cardiovasc Med. 2021;908. doi:10.3389/fcvm.2021.709872.
Sha, S.; Polidori, D.; Heise, T.; Natarajan, J.; Farrell, K.; Wang, S.-S.; Sica, D.; Rothenberg, P.; Plum-Mörschel, L. Effect of the Sodium Glucose Co-Transporter 2 Inhibitor Canagliflozin on Plasma Volume in Patients with Type 2 Diabetes Mellitus. Diabetes Obes. Metab. 2014, 16, 1087–1095.
Shin SJ, Chung S, Kim SJ, et al. Effect of Sodium‐Glucose Co‐Transporter 2 Inhibitor,Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.PLoS One. 2016;1(11):0165703. doi:10.1371/journal.pone.0165703.
Tadic, M.; Sala, C.; Saeed, S.; Grassi, G.; Mancia, G.; Rottbauer, W.; Cuspidi, C. New Antidiabetic Therapy and HFpEF: Light at the End of Tunnel? Heart Fail. Rev. 2022, 27, 1137–1146.
Гaдaeв A.Г., Турaкулoв Р.И., Қурбoнoв A.К., Тoшeвa Х.Б., Эркинoвa Н.A. Сурункaли юрaк eтишмoвчилиги кaмқoнлик билaн кeчгaндa дaвoлaш тaмoйиллaри // Тoшкeнт тиббиёт aкaдeмияси aхбoрoтнoмaси. – 2014. - №4. - С.71 -73. (14.00.00; №13).
Гaдaeв A.Г., Турaкулoв Р.И., Рaхимoвa М.Э. Cурункaли юрaк eтишмoвчилиги кaмқoнлик билaн кeчгaндa бeмoрлaрнинг ҳaёт сифaти вa жисмoний юклaмaгa чидaмлилик кўрсaткичлaри // Тoшкeнт тиббиёт aкaдeмияси aхбoрoтнoмaси. – 2014. - №4. – С.71 – 73.
License
Copyright (c) 2023 Abdigaffar G. Gadaev, Farida I. Khujakulova, Ravshan Q. Qarakhanov
This work is licensed under a Creative Commons Attribution 4.0 International License.
The content published on the International Scientific and Current Research Conferences platform, including conference papers, abstracts, and presentations, is made available under an open-access model. Users are free to access, share, and distribute this content, provided that proper attribution is given to the original authors and the source.
